Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab + lenalidomide + GemOx versus rituximab + GemOx in relapsed/refractory diffuse large B-cell lymphoma
CTR20241368Phase 3Active
- Sponsor
- Incyte
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tafasitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Incyte. Started Jun 2024; status: active.
02
Drugs
tafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20241368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241368.